4BIO Capital: Investment Portfolio & Startup News
4BIO Capital
To add a bio or update investment portfolio, please click update information.
Investment Portfolio
Undecimal Bio
13 Oct 2026
Undecimal Bio lands a £14m seed round led by 4BIO Capital and IQ Capital to unlock targeted delivery of RNA drugs beyond the liver
Undecimal Bio is a platform biotechnology company developing DELiveri, an AI-enabled synthetic biology platform for targeted delivery of siRNA therapeutics. DELiveri identifies conjugates that direct RNA medicines to defined cell types beyond the liver, with an initial focus on renovascular disease.
Cytospire Therapeutics
5 May 2026
Cytospire Therapeutics secures £61m Series A led by 4BIO Capital for cancer therapies that activate the body’s immune cells
Cytospire Therapeutics develops multispecific immune cell engager antibodies designed to enhance and direct the activity of the body’s immune system. Its platform targets gamma delta T cells to generate anti tumour immune responses for patients with cancer and other diseases.
4BIO Capital
- 2(12 months)
- 4biocapital.com
- Update Information
More venture news
- 15 Oct 2026
MedcotecMedcotec announces its £2.4m seed round from VCs to help pharma manufacturers transfer powders with single-use valves
SeedLife Sciences - 15 Oct 2026
Silvia BioSilvia Bio raises a £3m seed round led by Northern Gritstone to improve complex biopharmaceutical manufacturing
SeedLife Sciences - 13 Oct 2026
Alchera TechnologiesAlchera Technologies raises a £2.7m seed round led by Maven Capital Partners to analyse transport network data with AI
SeedMobility
